Table 2.

Proportion of infliximab discontinuation of the retransitioning cohort and the biosimilar remainder cohort.

Infliximab discontinuation	No. patients	6 months	1 year	End of follow-up
		n (%)	n (%)	n (%)
Overall infliximab discontinuation
Retransitioning cohort	44	0 (0%)	4 (9.1%)	11 (25.0%)
Biosimilar remainder cohort	127	12 (9.4%)	15 (11.8%)	29 (22.8%)
Discontinuation due to remission
Retransitioning cohort	44	0 (0%)	0 (0%)	1 (2.3%)
Biosimilar remainder cohort	127	6 (4.7%)	6 (4.7%)	12 (9.4%)
Discontinuation due to unwanted response
Retransitioning cohort	44	0 (0%)	4 (9.1%)	10 (22.7%)
Biosimilar remainder cohort	127	6 (4.7%)	9 (7.1%)	17 (13.4%)